Navigation Links
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
Date:4/23/2009

3 through 17 years receiving PEGINTRON/REBETOL combination therapy, weight loss and growth inhibition were common.

Patients receiving PEGINTRON and REBETOL as retreatment after failing a previous interferon combination regimen reported adverse reactions similar to those previously associated with this regimen during clinical trials of treatment-naive patients.

Please see important full U.S. prescribing information and the Medication Guide for PEGINTRON at www.schering-plough.com.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential market for PEGINTRON and REBETOL. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including uncertainties in the regulatory process, among other uncertainties. For further details
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015  Physicians and payers alone do not ... Patients are better informed and getting increasingly involved ... This shift in power is reshaping the healthcare ... marketing. As part of this evolving ... important to educate, communicate and engage patients throughout ...
(Date:7/31/2015)... , July 31, 2015  In today,s ever-changing marketplace, ... are increasingly mobile, increasingly connected, and increasingly impatient with ... of customer interaction channels and tools is driving call ... media. According to research by benchmarking ... counter (OTC) segment in a call center study realize ...
(Date:7/31/2015)... , July 31, 2015  Seeger Weiss LLP is reporting ... issued a warning letter to C.R. Bard, the manufacturer of ... adequate strides to correct violations the agency found at two ... violations after the FDA cited them during Inspectional Observations that ... Bard,s Tempe, AZ , location and on ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... presented at the 10th International Kidney Cancer Symposium ... pretreatment blood-based test, VeriStrat, was able to stratify ... combination of two targeted therapies, sunitinib (Sutent®) and ... tested VeriStrat Good had significantly longer progression free ...
... 14, 2011 Reata Pharmaceuticals, Inc. announced Friday a ... company,s lead program, bardoxolone methyl, and to continue advancing ... the following executives: Paul Audhya, MD, ... Hilary Malone, Ph.D., as Vice President and ...
Cached Medicine Technology:VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients 2VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients 3Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors 2Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors 3
(Date:7/31/2015)... ... 31, 2015 , ... The 2015 ALS Ice Bucket Challenge will officially get ... Red Sox honor Ice Bucket co-founders Pat Quinn and Pete Frates, the ALS community ... collaborative efforts among the ALS organizations to find treatments and cures for the disease. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently, ZKB ... of Ohio, Western Division (Case No. 3:15-cv-00397) involving the Implanon® contraceptive implant ... spontaneous migration of their Implanon® implants, inability to locate the implants, unsuccessful and ...
(Date:7/31/2015)... York, NY and Rockport, ME (PRWEB) , ... July 31, 2015 , ... The alarm ... photo op. , Glancing out of the window, he recalled that his equipment was ... 215 Chrystie Street tower, he jumped out of bed. , The photo speaks for ...
(Date:7/31/2015)... York, NY (PRWEB) , ... July 31, 2015 , ... ... kidney disease, according to a study published today in Nature Communications and led by ... conducted in mice, suggests that variations in the gene RTN1 led to greater production ...
(Date:7/31/2015)... ... July 31, 2015 , ... everMaya ... their latest designer handbag line will be named for Madeline Stuart, an 18-year-old ... the first globally recognized model with Down syndrome, gracing the front pages of ...
Breaking Medicine News(10 mins):Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3
... of the American College of Radiology suggests that ... in diagnostic imaging growth. Self-referred imaging is identified ... patients to their own on-site imaging services or the referral ... have financial interest. In the current political ...
... be tight last year just 39 seconds separated the top ... every second counts, riders do everything possible to gain a competitive ... latest in sports nutrition. Now there could be a new, ... aiming to shave vital seconds off their time beetroot juice. ...
... News) -- U.S. military personnel are at significantly increased ... study has found. The physical demands of ... prevalence of the painful joint disease, the researchers suggested ... Arthritis & Rheumatism . "Surprisingly, little is known ...
... up and down the court aspiring to NBA stardom. Now, ... to achieving their hoop dreams: sleep. In a study ... Mah, a researcher in the Stanford Sleep Disorders Clinic and ... college level were able to improve their on-the-court performance by ...
... the Samuel Waxman Cancer Research Foundation awarded individual grants ... collaborative grants and three ongoing individual grants. The Foundation ... more than $3.1 million. "Scientists are moving ... of enzymes and genes into therapies to eradicate cancer ...
... (THR) can be fast tracked to be discharged in two ... to a new study by researchers at Hospital for Special ... cut down on hospital-acquired infections, reduce hospital costs and improve ... safe it would be to discharge patients within two days ...
Cached Medicine News:Health News:Self-referral: A significant factor in imaging growth 2Health News:Research reveals new secret weapon for Le Tour 2Health News:Military Members Face Raised Risk of Osteoarthritis: Study 2Health News:Snooze you win? It's true for achieving hoop dreams, says Stanford study 2Health News:Snooze you win? It's true for achieving hoop dreams, says Stanford study 3Health News:The Samuel Waxman Cancer Research Foundation awards more than $3.1 million in grants 2Health News:The Samuel Waxman Cancer Research Foundation awards more than $3.1 million in grants 3Health News:Study shows fast track total hip replacement surgery is effective and safe 2
... Tri-Active is the result of ... the combination of three different methods ... to your skin. This treatment is ... of cellulite through the combined action ...
... is a CO2 laser system with CW ... for dealing with all therapeutic application in ... supplies medium-to-high intensities in super-pulsed mode, designed ... surgery. It is also capable of supplying ...
... the latest evolution of Smartepil family by ... system for epilation and transdermic vascular treatments. ... modern software, Smartepil II Plus allows for ... respect of the patients social life. The ...
... offers a new and efficient method applied ... Springing from ongoing research and development with ... just a light source, but rather a ... represents new horizons in pulsed-light-based technology, the ...
Medicine Products: